Salivary gland malignancies present significant diagnostic challenges because multiple tumor subtypes share overlapping microscopic architecture. Recent advances in molecular pathology have demonstrated that recurrent oncogenic fusions serve as definitive diagnostic hallmarks. Consequently, testing for these alterations helps differentiate aggressive malignancies from low-grade mimickers. Chromogenic RNA in situ hybridization has emerged as an innovative diagnostic method to identify these genetic events directly in tissue sections. By targeting unique exon junctions, this platform offers tissue morphology correlation alongside molecular precision. Therefore, surgical pathologists can achieve rapid, high-confidence classifications even in challenging head and neck biopsies.

The Diagnostic Challenge in Salivary Gland Tumors

Salivary gland neoplasms represent one of the most morphologically diverse groups of human tumors. Histological patterns often overlap considerably among benign lesions, low-grade carcinomas, and high-grade malignancies. For example, microsecretory adenocarcinoma closely resembles adenoid cystic carcinoma, pleomorphic adenoma, and secretory carcinoma under conventional light microscopy. Similarly, mucoepidermoid carcinoma frequently mimics squamoid lesions, adenosquamous carcinoma, or necrotizing sialometaplasia. Histomorphological evaluation alone often proves inadequate for an unequivocal diagnosis. Therefore, pathologists increasingly depend on ancillary testing to confirm tumor lineage. Molecular characterization has uncovered pathognomonic gene translocations that drive distinct tumor subtypes. Specifically, the novel MEF2C::SS18 gene fusion defines microsecretory adenocarcinoma. In contrast, the classic CRTC1::MAML2 translocation characterizes most mucoepidermoid carcinomas. Identifying these chimeric transcripts resolves diagnostic ambiguity and prevents overtreatment or undertreatment. However, conventional testing methods require substantial tissue, specialized instruments, and prolonged turnaround times. Many diagnostic centers lack dedicated next-generation sequencing infrastructure. As a result, clinical laboratories urgently require rapid, accessible, and morphologically intact molecular diagnostic techniques to support timely surgical management.

Principles of Chromogenic RNA In Situ Hybridization

Chromogenic RNA in situ hybridization utilizing BaseScope technology provides single-molecule detection of specific RNA transcripts directly in formalin-fixed, paraffin-embedded tissues. Traditional fluorescence in situ hybridization targets genomic DNA breakpoints. In contrast, this RNA-targeted approach detects expressional chimeric junction sequences with single-nucleotide sensitivity. The assay employs pairs of sequence-specific oligonucleotide probes designed to span the novel splice junction between fused exons. Consequently, hybridization occurs only when both probe components bind adjacently across the fusion junction. This stringent requirement virtually eliminates non-specific background binding. Subsequent enzymatic signal amplification generates bright, punctate chromogenic signals visible under a standard brightfield microscope. Thus, pathologists do not require expensive darkroom fluorescence setups or digital imaging filters. Most importantly, the technique preserves cellular and architectural context completely intact. Observers can directly correlate fusion expression with tumor cytology, stromal invasion, and surgical margins. Furthermore, the protocol runs on standard automated immunohistochemistry stainers. This compatibility enables seamless integration into routine anatomic pathology workflows across academic hospitals and high-volume diagnostic centers.

Validation Across MEF2C::SS18 and CRTC1::MAML2 Cohorts

Investigators recently assessed the diagnostic sensitivity and specificity of chromogenic RNA in situ hybridization across well-characterized tumor cohorts. The study examined sixteen cases of MEF2C::SS18 fusion-positive microsecretory adenocarcinoma and six cases of CRTC1::MAML2 fusion-positive mucoepidermoid carcinoma. In addition, the researchers evaluated three fusion-unknown mucoepidermoid carcinomas and one fusion-negative case. Probes specifically targeted exon 7 of MEF2C fused to exon 4 of SS18, as well as exon 1 of CRTC1 joined to exon 2 of MAML2. Remarkably, the assay detected fusion transcripts in 14 out of 16 microsecretory adenocarcinomas, establishing an 88% detection rate. Among known fusion-positive mucoepidermoid carcinomas, the test identified transcripts in 3 of 6 cases. Furthermore, the assay revealed CRTC1::MAML2 fusions in two of three previously uncharacterized mucoepidermoid carcinomas. Importantly, the fusion-negative control showed no aberrant chromogenic signal. Positivity ranged from 1+ to 2+ scores based on punctate dots per tumor cell. These findings illustrate that probe sets targeting conserved exon junctions reliably detect pathogenic transcripts. Consequently, the platform demonstrates substantial promise as an objective diagnostic tool for fusion-driven salivary neoplasms.

Comparative Advantages Over Conventional FISH and NGS

Pathologists traditionally rely on fluorescence in situ hybridization and next-generation sequencing for molecular confirmation. However, each standard modality presents distinct operational constraints. Fluorescence in situ hybridization uses split-apart DNA probes that cannot determine the precise partner gene or confirm active transcriptional expression. Furthermore, fluorescence signals quench rapidly over time, hindering retrospective archival review and collaborative second opinions. Next-generation sequencing offers comprehensive genomic profiling, yet it demands substantial amounts of extracted nucleic acids. Moreover, sequencing involves complex bioinformatics, high reagent costs, and turnaround times extending several weeks. In contrast, chromogenic RNA in situ hybridization circumvents these major bottlenecks. The chromogenic reaction produces permanent slides that pathologists can examine under ordinary brightfield light microscopes. Additionally, the method requires only minute tissue quantities, making it ideal for sparse core needle biopsies or fine-needle aspirates. Because the assay directly detects junctional messenger RNA, it confirms active oncogenic expression rather than silent genomic rearrangements. Therefore, this technology bridges the gap between basic histology and sophisticated molecular diagnostics.

Clinical Implications and Future Implementation

Accurate classification of salivary neoplasms directly dictates clinical decision-making and surgical planning. Microsecretory adenocarcinoma typically follows an indolent clinical course requiring conservative surgical resection. Conversely, mucoepidermoid carcinoma exhibits variable biological aggressiveness depending on histologic grade and fusion status. Identifying a CRTC1::MAML2 fusion confirms mucoepidermoid carcinoma and generally correlates with favorable clinical outcomes compared to fusion-negative mimics. Therefore, rapid molecular identification prevents misdiagnosis and avoids unnecessarily radical surgery or inappropriate adjuvant radiation. Nevertheless, clinical laboratories must address technical factors before widespread diagnostic adoption. For instance, tissue pre-analytics, decalcification, and prolonged formalin fixation can degrade messenger RNA integrity. Such degradation potentially explains false-negative results observed in older archival specimens. Standardized laboratory protocols and internal control probes targeting housekeeping genes remain essential to verify RNA preservation. As additional probe panels enter diagnostic pathology, laboratories can implement multiplexed assays for salivary, pulmonary, and soft tissue tumors. Ultimately, chromogenic RNA in situ hybridization democratizes molecular diagnostics, bringing advanced transcriptomic analysis into routine practice worldwide.

How does chromogenic RNA in situ hybridization differ from traditional FISH?

Traditional fluorescence in situ hybridization detects structural genomic rearrangements in DNA using fluorescent break-apart probes. Consequently, it requires darkroom fluorescence microscopy and specialized imaging software. In contrast, chromogenic RNA in situ hybridization identifies chimeric messenger RNA junctions using brightfield chromogenic dyes. This approach confirms active gene transcription while preserving cellular architecture. Furthermore, the resulting slides remain permanent, allowing pathologists to evaluate molecular alterations directly alongside morphological features using standard laboratory microscopes.

Why is fusion detection vital for microsecretory adenocarcinoma diagnosis?

Microsecretory adenocarcinoma displays deceptive histological patterns that closely resemble secretory carcinoma, adenoid cystic carcinoma, and pleomorphic adenoma. Because these tumors require completely different surgical and therapeutic approaches, diagnostic precision is paramount. Microsecretory adenocarcinoma characteristically harbors a recurrent MEF2C::SS18 gene fusion that is absent in other salivary neoplasms. Therefore, detecting this specific fusion transcript confirms the diagnosis unequivocally, ensuring patients avoid unnecessarily aggressive surgical resections or inappropriate adjuvant oncological therapies.

What factors can cause false-negative results in RNA-based hybridization assays?

The primary factor contributing to false-negative results in RNA-based assays is pre-analytical tissue degradation. Formalin over-fixation, delayed fixation, or harsh decalcification can fragment cellular messenger RNA, preventing probe binding. Additionally, alternative transcript splice variants or rare fusion partner rearrangements outside the targeted exon junctions can yield negative signals. Therefore, laboratories must routinely run positive control probes, such as housekeeping genes, to confirm RNA integrity before interpreting fusion assay results.

Disclaimer: This content is for informational and educational purposes only and should not be construed as medical advice or replace independent professional medical judgment. Consult qualified healthcare professionals or institutional protocols for diagnosing and treating specific conditions. Refer to the latest local and national guidelines for clinical practice.

References

1. Palsgrove DN et al. Fusion Detection in Microsecretory Adenocarcinoma and Mucoepidermoid Carcinoma Using Chromogenic RNA In Situ Hybridization: A Promising Alternative to DNA-Based Fluorescence In-Situ Hybridization. Mol Carcinog. 2026 Oct 25. doi: 10.1002/mc.70176. PMID: 42927643.
2. Bean GR, et al. RNA In Situ Hybridization Detection of CRTC1/3::MAML2 Fusions and LINC00473 in Mucoepidermoid Carcinomas and Hidradenomas of Breast, Salivary Glands, and Skin. Mod Pathol. 2025;38(7):100756. doi: 10.1016/j.modpat.2025.100756.
3. Bishop JA, Sajed DP, Weinreb I, Dickson BC. Microsecretory Adenocarcinoma: A Novel Salivary Gland Tumor Characterized by a Recurrent MEF2C-SS18 Fusion. Am J Surg Pathol. 2019;43(8):1023-1032. doi: 10.1097/PAS.0000000000001284.